Clinical Trial Search

Primary: Annualized LRNC Volume Change in Carotid Plaque Composition, as Assessed by MRI — -4.6; -15.1; -9.4 mm^3/year

Primary: Change in Necrotic Core Volume — 0.07 mm^2

Primary: C-Reactive Protein (CRP) — 3.7; 4.6 mg/L

Primary: Mean Coronary Wall Thickness — 2.0 mm

Primary: Coronary Endothelial Function Measured by Percent Change in Coronary Blood Flow With Exercise (%) at 8 Weeks — 8.1; 13.4 Percent change from rest measurement

Primary: Changing LDL Cholesterol — 100; 70 Mg/dl

Primary: Number of Major Adverse Cardiac Events (MACE) — 9; 6; 2; 119 Participants

Primary: Change in Carotid Intima-media Thickness From Baseline to Year 1 — 0.766; 0.765; 0.758; 0.768 millmeter — p=0.7279

Primary: Change in Nitric Oxide Formation From Baseline to 3 Months. — 10.0; 11.2; 10.0; 11.0 ng/mL

Primary: Percent Change From Baseline in Mean Wall Thickness — 4.245; 6.679 Percent Change

Primary: CT Angiography Plaque — 0.17; -1.53 percent change of low attenuation plaque

Primary: Progression Rates of Low Attenuation Plaque Under Influence of Vascepa as Compared to Placebo as a Change Between Two or More Time Points — -0.3; 0.9 volume in mm cubed

Primary: Change From Baseline in Percent Atheroma Volume(PAV) After 104 Weeks of Treatment — -0.33; 0.11 percentage of baseline

Primary: Change in Noncalcified Coronary Artery Plaque Volume (NCPV) — -45 mm^3

Primary: Change in Mean of Wall Volume of Internal Carotid Arteries — -3.52; -5.91 Other - mm^3 ( cubic millimeter )

Primary: Percent Change in Coronary Cross Sectional Area (CSA) From Rest to That During Isometric Handgrip Exercise (IHE) — -1.70; 2.71; -0.39; 2.04 Percent change from rest…

Primary: Percent Agreement Between Coronary Calcium Score (CCS) and National Cholesterol Education Program (NCEP) Guidelines — 18 percent agreement

Primary: The Area Under the Receiver Operating Characteristic Curve of the CAD-score to Separate CAD From Non-CAD Patients. — 73.4 percentage of 100

Primary: Arterial Stiffness (Carotid Artery Compliance) During Saline — 1.31; 1.34; 0.90; 1.02 mm2/mm Hg×10-1

Primary: Number of Participants Stratified as Non-Index Culprit Lesion Related Major Adverse Cardiac Events (NC-MACE) or No NC-MACE and Association With maxLCBI4mm as a…

Primary: Change in Nitric Oxide Formation From Baseline to 3 Months — 27.6; 27.0; 31.4; 25.7 ng/mL

Primary: High-sensitivity C-reactive Protein — 1.0; 1.0 mg/dl — p=0.22

Primary: Table 1 Study Specific Characteristic Part One — 69.8; 59.8; 59.1; 72.7 Percentage of Participants — p=>0.05

Primary: Percent Change From Baseline (Before the Start of Rosuvastatin Treatment) to Week 76 in the Plaque Volume (PV) — 14.1 Percent Change

Primary: Change From Baseline in Carotid Femoral-Pulse Wave Velocity at Month 6 — 1.07; 0.99 meters per second (m/s)

Primary: Number of Participants Analyzed for Coronary Calcium Burden by AGS — 9; 11 Participants

Primary: Change From Baseline in Common Carotid Artery Intima-Media Thickness (IMT) — 0.877; 0.879; 0.036; 0.033 mm

Primary: Percent Change in Atheroma Volume (PAV) in the Thoracic Aorta of Spironolactone vs. Placebo — 0.5; 7.3 percentage change — p=0.0293

Primary: Change in Post-exercise Coronary Vasodilator Reserve — -4; 2 % change

Primary: Percentage Change in Coronary Artery Diameter — 3; 3 % change coronary artery diameter